[
  {
    "ts": "2025-11-17T09:35:00+00:00",
    "headline": "Down 55%, Should You Buy the Dip on Pfizer?",
    "summary": "Pfizer is a pharmaceutical industry giant facing normal pharmaceutical industry headwinds; it will survive.",
    "url": "https://www.fool.com/investing/2025/11/17/down-55-buy-the-dip-pfizer-stock/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "2947fab7-2769-334a-ad17-4ed3f745f125",
      "content": {
        "id": "2947fab7-2769-334a-ad17-4ed3f745f125",
        "contentType": "STORY",
        "title": "Down 55%, Should You Buy the Dip on Pfizer?",
        "description": "",
        "summary": "Pfizer is a pharmaceutical industry giant facing normal pharmaceutical industry headwinds; it will survive.",
        "pubDate": "2025-11-17T09:35:00Z",
        "displayTime": "2025-11-17T09:35:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/68a63437233737c46261a8dae6359332",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "A doctor talking to a smiling parent and child in a medical setting.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yp.MpXx..hxcEr1ZJV385g--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/68a63437233737c46261a8dae6359332.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kOpKa0GOJnOuBwBwoCmR7g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/68a63437233737c46261a8dae6359332.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/17/down-55-buy-the-dip-pfizer-stock/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/down-55-buy-dip-pfizer-093500557.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-17T15:00:00+00:00",
    "headline": "2 Giant Healthcare Stocks to Buy Hand Over Fist in November",
    "summary": "Consider buying Medtronic for its dividend and Pfizer for its turnaround potential if you are looking for attractive healthcare investments in November.",
    "url": "https://www.fool.com/investing/2025/11/17/2-giant-healthcare-stocks-to-buy-hand-over-fist-in/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "abbfc7b9-4bb6-3068-8457-ccfb5da0eda1",
      "content": {
        "id": "abbfc7b9-4bb6-3068-8457-ccfb5da0eda1",
        "contentType": "STORY",
        "title": "2 Giant Healthcare Stocks to Buy Hand Over Fist in November",
        "description": "",
        "summary": "Consider buying Medtronic for its dividend and Pfizer for its turnaround potential if you are looking for attractive healthcare investments in November.",
        "pubDate": "2025-11-17T15:00:00Z",
        "displayTime": "2025-11-17T15:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/cc7abf48fbeef64c80bea9a95107e993",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "A person drawing a picture of a large fish getting ready to swallow a smaller fish.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_IhPTxrGzCXJ08.z9Vfm7g--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/cc7abf48fbeef64c80bea9a95107e993.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AqYd1da6NLDMX6MA.ADl8g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/cc7abf48fbeef64c80bea9a95107e993.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/17/2-giant-healthcare-stocks-to-buy-hand-over-fist-in/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-giant-healthcare-stocks-buy-150000883.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MDT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-17T14:39:44+00:00",
    "headline": "Johnson & Johnson Inks A $3.05 Billion Deal In Cancer Treatment",
    "summary": "Johnson & Johnson said Monday it's putting up $3.05 billion to buy privately held cancer player Halda Therapeutics.",
    "url": "https://www.investors.com/news/technology/johnson-johnson-halda-therapeutics-acquisition/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "c8ae5711-9ede-37cc-a6d8-8dd58be67929",
      "content": {
        "id": "c8ae5711-9ede-37cc-a6d8-8dd58be67929",
        "contentType": "STORY",
        "title": "Johnson & Johnson Inks A $3.05 Billion Deal In Cancer Treatment",
        "description": "",
        "summary": "Johnson & Johnson said Monday it's putting up $3.05 billion to buy privately held cancer player Halda Therapeutics.",
        "pubDate": "2025-11-17T14:39:44Z",
        "displayTime": "2025-11-17T14:39:44Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/c8ae5711-9ede-37cc-a6d8-8dd58be67929/johnson-johnson-inks-a.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/d47003b69a5bd930672a446b220fd7c8",
          "originalWidth": 1012,
          "originalHeight": 572,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/N8_T59Ega2m9fWYxF8q0BA--~B/aD01NzI7dz0xMDEyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/d47003b69a5bd930672a446b220fd7c8.cf.webp",
              "width": 1012,
              "height": 572,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EpSVohaMNWkiha7A6oNYxw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/d47003b69a5bd930672a446b220fd7c8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/johnson-johnson-halda-therapeutics-acquisition/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-17T13:33:00+00:00",
    "headline": "MRK to Buy Cidara for $9.2B: Focus on Buyout Spree Heading Into 2026",
    "summary": "Merck's $9.2 billion proposed Cidara acquisition will add CD388 to the pipeline, boosting the respiratory portfolio and fueling its ongoing strategic M&A momentum.",
    "url": "https://finance.yahoo.com/news/mrk-buy-cidara-9-2b-133300023.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "538314f1-4860-3737-9c1a-55dced09b1bf",
      "content": {
        "id": "538314f1-4860-3737-9c1a-55dced09b1bf",
        "contentType": "STORY",
        "title": "MRK to Buy Cidara for $9.2B: Focus on Buyout Spree Heading Into 2026",
        "description": "",
        "summary": "Merck's $9.2 billion proposed Cidara acquisition will add CD388 to the pipeline, boosting the respiratory portfolio and fueling its ongoing strategic M&A momentum.",
        "pubDate": "2025-11-17T13:33:00Z",
        "displayTime": "2025-11-17T13:33:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/1b28b8f55ab25205feceb1a2771a2b3a",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RRg0vYpNavphT7S8O9jT7w--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1b28b8f55ab25205feceb1a2771a2b3a.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hIkvgr9e5vaptAEV_vkcVg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1b28b8f55ab25205feceb1a2771a2b3a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/mrk-buy-cidara-9-2b-133300023.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/mrk-buy-cidara-9-2b-133300023.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-17T10:27:00+00:00",
    "headline": "PLX: Protalix Seeks Re-Examination of CHMP Opinion",
    "summary": "By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Third Quarter 2025 Financial and Operational Review Protalix BioTherapeutics, Inc. (NYSE:PLX) announced 3Q:25 financial and operational results in a November 13 th , 2025, press release and in its Form 10-Q filing. The reports were followed by a conference call, which discussed recent achievements, regulatory updates, trial",
    "url": "https://finance.yahoo.com/news/plx-protalix-seeks-examination-chmp-102700390.html",
    "source": "Zacks Small Cap Research",
    "provider": "yfinance",
    "raw": {
      "id": "e806af6c-6bea-3c13-84a6-0104ec8bfc01",
      "content": {
        "id": "e806af6c-6bea-3c13-84a6-0104ec8bfc01",
        "contentType": "STORY",
        "title": "PLX: Protalix Seeks Re-Examination of CHMP Opinion",
        "description": "",
        "summary": "By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Third Quarter 2025 Financial and Operational Review Protalix BioTherapeutics, Inc. (NYSE:PLX) announced 3Q:25 financial and operational results in a November 13 th , 2025, press release and in its Form 10-Q filing. The reports were followed by a conference call, which discussed recent achievements, regulatory updates, trial",
        "pubDate": "2025-11-17T10:27:00Z",
        "displayTime": "2025-11-17T10:27:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/scr.zacks.com/ded098717fc89106beae2ae443ab4696",
          "originalWidth": 1576,
          "originalHeight": 636,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Dpaws0xKXWMCr8ni270Mag--~B/aD02MzY7dz0xNTc2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/ded098717fc89106beae2ae443ab4696.cf.webp",
              "width": 1576,
              "height": 636,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mOHtRr.7uxIU_bHo3ThXow--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/scr.zacks.com/ded098717fc89106beae2ae443ab4696.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks Small Cap Research",
          "url": "http://scr.zacks.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/plx-protalix-seeks-examination-chmp-102700390.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/plx-protalix-seeks-examination-chmp-102700390.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PLX"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-17T18:20:00+00:00",
    "headline": "Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion",
    "summary": "Halda is testing a prostate cancer drug. J&J says that with the acquisition it will gain a platform for treating “diseases beyond oncology.”",
    "url": "https://www.barrons.com/articles/johnson-johnson-cancer-drugmaker-halda-therapeutics-60d9b4b0?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "3026b6e4-952c-3dab-87ba-9a360db8b96b",
      "content": {
        "id": "3026b6e4-952c-3dab-87ba-9a360db8b96b",
        "contentType": "STORY",
        "title": "Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion",
        "description": "",
        "summary": "Halda is testing a prostate cancer drug. J&J says that with the acquisition it will gain a platform for treating “diseases beyond oncology.”",
        "pubDate": "2025-11-17T18:20:00Z",
        "displayTime": "2025-11-17T18:20:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/3026b6e4-952c-3dab-87ba-9a360db8b96b/johnson-johnson-will-buy.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/fa25673e917527d59383d43653f921ec",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ObQCDWUdeqn9864I76st_g--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/fa25673e917527d59383d43653f921ec.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KBOPtMARGiCnOQhvt6Wx.g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/fa25673e917527d59383d43653f921ec.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/johnson-johnson-cancer-drugmaker-halda-therapeutics-60d9b4b0?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "XBI"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]